We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Elevated Cytokine Levels Linked to Future Development of Myocardial Infarction

By LabMedica International staff writers
Posted on 17 May 2021
Elevated levels of the plasma biomarkers interleukin-6 (IL-6) and the IL-6 binary complex have been linked to the increased risk of myocardial infarction (MI) found in smokers and individuals with hypertension.

IL-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. More...
It is secreted by macrophages in response to specific microbial molecules, referred to as pathogen-associated molecular patterns (PAMPs). These PAMPs bind to an important group of detection molecules of the innate immune system, called pattern recognition receptors (PRRs), including Toll-like receptors (TLRs). These are present on the cell surface and intracellular compartments and induce intracellular signaling cascades that give rise to inflammatory cytokine production. IL-6 is an important mediator of fever and of the acute phase response. The importance of IL-6 trans-signaling associated with risk of future myocardial infarction has not been studied to any great extent. Furthermore, whether elevation in IL-6 explains part of the association between traditional risk factors and future MI has not been explored.

In this regard, investigators at Örebro University (Sweden) sought to evaluate the association of plasma concentrations of IL-6 and IL-6 binary complex with the potential for future development of MI. IL-6 binary complex is a novel biomarker estimated from plasma concentration of IL-6, sIL-6R (soluble IL-6 receptor), and sgp130 (soluble-glycoprotein130) that reflects the extent of systemic IL-6 trans-signaling.

For this study, the investigators conducted a nested case-control study including a total of 584 participants (292 cases and 292 controls). At baseline, plasma cholesterol levels were measured, and clinical characteristics of participants were collected. The investigators measured the plasma concentration of IL-6, sIL-6R, and sgp130 and estimated the concentration of the IL-6 binary complex.

Results revealed that IL-6 binary complex concentration was significantly elevated in participants who experienced MI compared with those who did not. Furthermore, exposure to traditional cardiovascular disease risk factors contributed to elevated concentration of IL-6 binary complex. Univariate analyses showed that a 10-fold increase in IL-6 binary complex was associated with a 3.6 times higher risk of future MI. In addition, the investigators found a statistically significant indirect effect of smoking and hypertension on future MI that was mediated through increased IL-6 binary complex or plasma IL-6.

"What is unique about this study is that we have only studied the inflammatory aspects of IL-6. We have measured the levels of inflammatory IL-6 in the blood," said senior author Dr. Liza Ljungberg, senior lecturer in medical sciences at Örebro University. "Focusing on solely reducing the inflammatory characteristics of IL-6 could reduce inflammation without other important functions in the body being impaired. This means that serious side effects of the medication can be avoided."

The link between IL-6 and MI was discussed in the April 2021 issue of the journal Atherosclerosis, Thrombosis and Vascular Biology.

Related Links:
Örebro University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.